Sign Up Today and Learn More About Lymphatica Medtech Stock
Invest in or calculate the value of your shares in Lymphatica Medtech or other pre-IPO companies through EquityZen's platform.
Lymphatica Medtech Stock (LYME)
Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.
About Lymphatica Medtech Stock
Founded
2017
Industries
Software, Artificial Intelligence, Data and Analytics
Lymphatica Medtech Press Mentions
Stay in the know about the latest news on Lymphatica Medtech
Systems and methods for a bodily fluid drainage system
patents • Feb 09, 2025
Lymphatica Medtech closes €17.9 million funding round to drive innovation in lymphedema treatment
med-technews • Dec 28, 2024
Swiss startup news
venturelab • Dec 17, 2024
Swiss startup news
venturelab • Dec 02, 2024
Swiss startup news
venturelab • Nov 19, 2024
Lymphatica Medtech Management
Leadership team at Lymphatica Medtech
Co-Founder & COO
Valentina Triacca
Board Member
Lukas Guenther
Join now and verify your accreditation status to gain access to:
- Lymphatica Medtech Current Valuation
- Lymphatica Medtech Stock Price
- Lymphatica Medtech Management
- Available deals in Lymphatica Medtech and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Lymphatica Medtech Cap Table and Funding History by Share Class and Liquidity Preferences
- Lymphatica Medtech Revenue and Financials
- Lymphatica Medtech Highlights
- Lymphatica Medtech Business Model
- Lymphatica Medtech Risk Factors
- Lymphatica Medtech Research Report from SACRA Research
Trading Lymphatica Medtech Stock
How to invest in Lymphatica Medtech stock?
Accredited investors can buy pre-IPO stock in companies like Lymphatica Medtech through EquityZen funds. These investments are made available by existing Lymphatica Medtech shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Lymphatica Medtech stock?
Shareholders can sell their Lymphatica Medtech stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
